News – Abzena

Filter by year

Filter by topic

Abzena to pursue $12 million investment program to upgrade and expand its San Diego biomanufacturing operations

San Diego CA, USA, 26 April 2017 – Abzena intends to invest $12 million at its San Diego facilities in order to upgrade and expand its biomanufacturing capabilities and capacity to meet increasing customer demand for its services. This investment was made possible following the Company’s recent $32 million financing via a share placing on […] Read more

Abzena to pursue $5 million investment program in Bristol

Bristol PA, USA, 26 April 2017 – Abzena intends to invest $5 million at its Bristol PA facility in order to increase its chemistry research and manufacturing services business for the biopharmaceutical industry. This investment was made possible following the Company’s recent $32 million financing via a share placing on the London Stock Exchange. Abzena […] Read more

Result of General Meeting

Cambridge, UK, 21 April 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’) the life sciences group providing services and technologies to enable the development and manufacture of better biopharmaceutical products, announced on 5 April 2017 a conditional placing to raise approximately £25 million (the “Placing Announcement”).  The Placing was subject to inter alia […] Read more

A short history of monoclonal antibody research in Cambridge

Abzena’s CEO John Burt features in this short film by Cambridge TV. It leads us through a short history of monoclonal antibody research in the Cambridge life science cluster and asks what the next big thing will be in this area of exciting medical technology. John talks on the benefits of  antibody drug conjugates and […] Read more

Result of Bookbuild

NOT FOR RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL. Abzena plc RESULT OF BOOKBUILD Cambridge, UK, 5 April 2017 – Abzena plc (“Abzena” or the […] Read more

Proposed placing of £25m

NOT FOR RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE. Abzena plc PROPOSED PLACING OF £25 MILLION Proceeds […] Read more

‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial

Cambridge, UK, 6 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that one of the ‘Abzena inside’ Composite Human Antibody™ products previously disclosed as being in Phase I trials is moving forwards into a Phase […] Read more

Abzena plc – Partner Halozyme to present poster at AACR

Cambridge, UK, 3 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, notes that partner Halozyme Therapeutics’ (“Halozyme”) has published an abstract for its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting […] Read more

Abzena plc and UCL Medical Research Council grant awarded to collaboration group developing novel autoimmune therapy

Cambridge and London, UK, 1 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products and UCL (University College London), one of the world’s leading multidisciplinary universities, supported by UCL Business, the technology commercialisation company of UCL, […] Read more

Trading and business update

Cambridge, UK, 21 February 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, provides the following business update for the period to 20 February 2017. Highlights Group revenue for the full year expected to be in line with […] Read more

Interested in our services? Get In Touch